Feb 26, 2026 Bone biofabrication is rapidly moving from experimental scaffolds to increasingly functional, vascularized bone constructs tailored to individual patients, with academia leading in new biomaterials, multi‑material bioprinting, and bone organoids for regeneration and disease modeling. At the same time, commercial players in bone regeneration and 3D bioprinting are scaling platforms for patient‑specific grafts and implants, feeding into a global bone regeneration market of roughly 5.8–6.2 billion USD in 2025 and a broader 3D bioprinting market of about 2.6 billion USD, both projected to grow steadily over the next decade on the back of orthopedic and dental demand.[Ref] Yet despite impressive progress, both academic and commercial communities still face major hurdles, including bioinks with sufficient mechanical strength for load‑bearing bone, long‑term vascularization and integration, regulatory pathways, and scalable manufacturing that meets cost and quality expectations for hospitals and industry partners. These challenges, together with fast‑growing applications in large bone defect repair, cranio‑maxillofacial reconstruction, spinal fusion, dental implants, and in‑vitro bone models for drug testing, make this the right moment to convene scientists, clinicians, engineers, investors, and entrepreneurs in a virtual event to share data, stress‑test business models, and build collaborations that can push bone biofabrication from promising prototypes into routine clinical and commercial reality.[Ref]
Apply to speak or sponsor the event: info@3dheals.com
Subscribe here to receive event emails.
Speakers:
Rao S. Bezwada
An accomplished scientist and entrepreneur, Rao S. Bezwada, Ph.D. established Bezwada Biomedical, an innovation-based and technology-driven research company, in 2003. The company is focused on developing a wide range of novel absorbable polymeric biomaterials to enhance quality of life by producing next generation bioabsorbable medical devices with therapeutic applications. Dr. Bezwada earned a doctorate in chemistry from the Stevens Institute of Technology in New Jersey and has over 40 years of research experience in the medical device industry, including 20 years of service at Ethicon, Inc. (a Johnson & Johnson Company). While at Ethicon, Dr. Bezwada’s research and development efforts led to the launch of a number of products, including Monocryl®, a new ultra-pliable synthetic absorbable monofilament suture. This product has represented worldwide sales of more than two (2) billion dollars since its launch in 1993 and current annual sales of over 100 million dollars. The development of Monocryl, is a testament to Dr Bezwada’s innovative prowess. Not only has this product significantly impacted medical practices worldwide, but its success also earned him the prestigious Johnson medal from Johnson and Johnson in 1996. His prolific inventiveness, as evidenced by over 150 issued US patents on absorbable polyurethanes, absorbable amino acid polymers, absorbable polyester amides, absorbable polyoxaesters, and controlled release polymers, underscores his dedication to pushing the boundaries of biomedical technology. Dr Bezwada’s leadership and guidance has led to the creation of more than 10 FDA-approved products including MONTAGE® Putty, MONTAGE Fast Set Putty, Montage Flowable Putty, and PERMATAGE Putty, marketed by Abyrx for wound healing and bone applications, all based on Bezwada Biomedical’s absorbable polyurethane technology.
Neeti Srivastava
Dr. Neeti Srivastava has been a key member of Bezwada Biomedical since 2009, bringing over 15 years of experience in biomedical research and a Ph.D. in Biochemistry. With deep expertise in absorbable polymers, drug delivery systems, biomaterials, and quality management systems, Dr. Srivastava leads research and development, business development, and quality assurance, always focusing on creating innovative, safe, and effective solutions to improve patient care.
Dr. Srivastava has extensive knowledge of Bezwada’s absorbable polyurethane technology, including bio-based polyurethanes, and holds patents on the technology, solidifying her position as a leader in polymer science. Her contributions were essential in the creation of TissuBond™, a tissue adhesive that secured NSF SBIR Phase I and II grants. She also worked on absorbable polyurethane formulations for a bone hemostat product that received 510(k) approval from the FDA and was commercialized as MONTAGE® by Abyrx, Inc.
Her leadership and dedicated efforts were instrumental in Bezwada Biomedical’s achievement of ISO 9001 and ISO 13485 certifications. Through her guidance in building a robust quality management system, she has ensured the company’s commitment to delivering safe and effective polymers that meet the highest regulatory standards.
Dr. Srivastava is also an established voice in the scientific community, having authored multiple scholarly articles and presented her research at esteemed conferences such as the American Chemical Society and the Society for Biomaterials. Her work continues to drive both academic and industrial advancements in biomedical science and drug delivery technologies.
Monica Wellejus
Monica Wellejus is a technology commercialization strategist who has spent almost seven years working at the intersection of biomaterials and medical 3D printing. With an MA in Business, Language, and Culture, Monica entered the field from a non-technical angle but quickly became involved in all aspects of bringing bone regenerative solutions to market, from product development and quality control to regulatory pathways, evidence generation, and global commercialization strategies. She has been part of Ossiform® since 2019, where she manages the company’s commercial and go-to-market activities as the Chief Commercial Officer.
Ossiform® develops bio-integrative bone substitutes with tailored structural properties to improve bone healing outcomes, simplify complex procedures, and reduce complication rates in orthopedics and spine. Its novel 3D printing technology is further used to provide bone-mimicking 3D cell culture systems for improving the physiological relevance of in vitro models in bone and cancer research.
Moderator:
Dr. Jenny Chen
Dr. Jenny Chen is trained as a neuroradiologist, and founder/CEO of 3DHEALS. Her main interests include next-generation education, 3D printing in the healthcare sector, automated biology, and artificial intelligence. She is an angel investor who invests in Pitch3D companies.
Thanks to our sposor:
Comments